Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Total Liabilities: 2023-2025

Historic Total Liabilities for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $21.3 million.

  • Tonix Pharmaceuticals Holding's Total Liabilities rose 2.50% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 2.50%. This contributed to the annual value of $23.3 million for FY2024, which is 52.32% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Total Liabilities of $21.3 million as of Q3 2025, which was up 10.02% from $19.4 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Total Liabilities high stood at $48.9 million for Q4 2023, and its period low was $12.5 million during Q1 2025.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Total Liabilities had a median value of $20.8 million in 2024 and averaged $23.0 million.
  • In the last 5 years, Tonix Pharmaceuticals Holding's Total Liabilities skyrocketed by 99.11% in 2024 and then plummeted by 54.14% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Total Liabilities (Quarterly) stood at $48.9 million in 2023, then plummeted by 52.32% to $23.3 million in 2024, then grew by 2.50% to $21.3 million in 2025.
  • Its last three reported values are $21.3 million in Q3 2025, $19.4 million for Q2 2025, and $12.5 million during Q1 2025.